TY - JOUR
T1 - Biosimilars for retinal diseases
T2 - United States-Europe awareness survey (Bio-USER–survey)
AU - International Retina Biosimilar Study Group (Inter BIOS Group)
AU - International Retina Biosimilar Study Group (Inter BIOS Group)
AU - Bandello, Francesco
AU - Querques, Giuseppe
AU - Loewenstein, Anat
AU - Özdek, Şengül
AU - Rezai, Kourous
AU - Laurent, Kodjikian
AU - Bilgic, Alper
AU - Lanzetta, Paolo
AU - Zur, Dinah
AU - Yannuzzi, Nicolas
AU - Corradetti, Giulia
AU - Kaiser, Peter
AU - Hilely, Assaf
AU - Boyer, David
AU - Rachitskaya, Aleksandra
AU - Chakravarthy, Usha
AU - Wintergerst, Maximilian
AU - Sarao, Valentina
AU - Parolini, Barbara
AU - Mruthyunjaya, Prithvi
AU - Nguyen, Quan Dong
AU - DO, Diana
AU - Keane, Pearse A.
AU - Hassan, Tarek
AU - Sridhar, Jayanth
AU - Eichenbaum, David
AU - Grewal, Dilraj
AU - Splitzer, Martin
AU - Sharma, Ashish
AU - Holz, Frank G.
AU - Regillo, Carl D.
AU - Freund, K. Bailey
AU - Sarraf, David
AU - Khanani, Arshad M.
AU - Baumal, Caroline
AU - Holekamp, Nancy
AU - Tadayoni, Ramin
AU - Kumar, Nilesh
AU - Parachuri, Nikulaa
AU - Kuppermann, Baruch D.
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Purpose: To assess the awareness of biosimilar intravitreal anti-VEGF agents among retina specialists practicing in the United States (US) and Europe. Methods: A 16-question online survey was created in English and distributed between Dec 01, 2021 and Jan 31, 2022. A total of 112 respondents (retinal physicians) from the US and Europe participated. Results: The majority of the physicians (56.3%) were familiar with anti-VEGF biosimilars. A significant number of physicians needed more information (18.75%) and real world data (25%) before switching to a biosimilar. About one half of the physicians were concerned about biosimilar safety (50%), efficacy (58.9 %), immunogenicity (50%), and their efficacy with extrapolated indications (67.8 %). Retinal physicians from the US were less inclined to shift from off-label bevacizumab to biosimilar ranibizumab or on-label bevacizumab (if approved) compared to physicians from Europe (p=0.0001). Furthermore, physicians from the US were more concerned about biosimilar safety (p=0.0371) and efficacy compared to Europe (p= 0.0078). Conclusions: The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.
AB - Purpose: To assess the awareness of biosimilar intravitreal anti-VEGF agents among retina specialists practicing in the United States (US) and Europe. Methods: A 16-question online survey was created in English and distributed between Dec 01, 2021 and Jan 31, 2022. A total of 112 respondents (retinal physicians) from the US and Europe participated. Results: The majority of the physicians (56.3%) were familiar with anti-VEGF biosimilars. A significant number of physicians needed more information (18.75%) and real world data (25%) before switching to a biosimilar. About one half of the physicians were concerned about biosimilar safety (50%), efficacy (58.9 %), immunogenicity (50%), and their efficacy with extrapolated indications (67.8 %). Retinal physicians from the US were less inclined to shift from off-label bevacizumab to biosimilar ranibizumab or on-label bevacizumab (if approved) compared to physicians from Europe (p=0.0001). Furthermore, physicians from the US were more concerned about biosimilar safety (p=0.0371) and efficacy compared to Europe (p= 0.0078). Conclusions: The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.
KW - Anti-VEGF
KW - Bio-USER
KW - United States
KW - awareness
KW - biosimilar
KW - europe
KW - ophthalmology
KW - retina
KW - survey
UR - http://www.scopus.com/inward/record.url?scp=85148608407&partnerID=8YFLogxK
U2 - 10.1080/14712598.2023.2176218
DO - 10.1080/14712598.2023.2176218
M3 - Article
C2 - 36726203
AN - SCOPUS:85148608407
SN - 1471-2598
VL - 23
SP - 851
EP - 859
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 8
ER -